Sera Prognostics (NASDAQ:SERA) Trading Down 2.8% – Here’s What Happened

Sera Prognostics, Inc. (NASDAQ:SERA) dropped 2.8% on Thursday . The company traded as low as $2.78 and last traded at $2.80. Approximately 24,971 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 54,412 shares. The stock had previously closed at $2.88.

Wall Street Analysts Forecast Growth

SERA has been the subject of a number of research reports. Jefferies Financial Group raised shares of Sera Prognostics to a “strong-buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded Sera Prognostics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Sera Prognostics presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics Price Performance

The stock has a 50 day simple moving average of $3.31 and a 200-day simple moving average of $3.11. The firm has a market cap of $106.54 million, a PE ratio of -3.58 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.10 million. As a group, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 28,215 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60. Following the transaction, the chief executive officer directly owned 768,081 shares in the company, valued at $2,334,966.24. This represents a 3.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 52,587 shares of company stock worth $163,108. Company insiders own 13.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC purchased a new position in Sera Prognostics during the fourth quarter valued at approximately $31,000. Abel Hall LLC acquired a new stake in Sera Prognostics during the 2nd quarter worth $31,000. Riverview Capital Advisers LLC acquired a new position in Sera Prognostics during the second quarter worth about $35,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Sera Prognostics in the third quarter valued at approximately $38,000. Finally, Lido Advisors LLC acquired a new stake in shares of Sera Prognostics in the 3rd quarter worth $68,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.